Jubilant Pharmova Limited
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Jubilant Pharmova Limited's yearly results (2023–2026), compared with Healthcare companies in India. Tap ? on any ratio for what it means.
What stands out
- Tangible Net Worth Ratio: Of every ₹100 of net worth, ₹42 is tangible; the rest is goodwill and other intangibles, often from buying other companies. Less tangible than 91% of Healthcare companies in India.
- Profit Cash Ratio: Over the last 3 years, every ₹100 of reported profit came with ₹249 of operating cash. Higher than 91% of Healthcare companies in India.
- Tangible Assets Ratio: Of every ₹100 the company owns, ₹74 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles. Less tangible than 89% of Healthcare companies in India.
Where ₹100 of sales goes
Latest year (Mar 2026). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
₹249Over the last 3 years, every ₹100 of reported profit came with ₹249 of operating cash.
Higher than 91% of Healthcare companies in India.
Self-Funding Ratio
0.9×Over the last 3 years its own operating cash paid for 94% of its investment spending (capex); the rest came from other sources such as borrowing, cash reserves or new shares.
Lower than 68% of Healthcare companies in India.
Cash Locked Ratio
₹5For every ₹100 of sales, ₹5 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against ₹17 tied up three years earlier.
Less money tied up than 80% of Healthcare companies in India.
Growth quality
Steadiness Ratio
3/3 · 2/3Sales grew in 3 of the last 3 years; profit grew in 2 of 3.
Steadier than 53% of Healthcare companies in India.
Growth Efficiency Ratio
₹23Sales grew 32% in 3 years; of every extra ₹100 of sales, ₹23 became extra profit.
Higher than 69% of Healthcare companies in India.
Asset Productivity Ratio
+32% / +39%In 3 years sales changed by +32% while total assets changed by +39%. Assets grew faster than sales.
Balance-sheet strength
Debt Due Cover Ratio
5.0×Debt due within a year is covered 5.0 times by its yearly operating cash.
Higher than 69% of Healthcare companies in India.
Cash Cushion Ratio
−16%Debt, after subtracting cash, equals 16% of its market value (net debt).
Lower than 87% of Healthcare companies in India.
Tangible Assets Ratio
74%Of every ₹100 the company owns, ₹74 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
Less tangible than 89% of Healthcare companies in India.
Tangible Net Worth Ratio
42%Of every ₹100 of net worth, ₹42 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
Less tangible than 91% of Healthcare companies in India.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (14)
Jubilant Pharmova Limited owes ₹0.54 for every ₹1 it owns. Net profit fell 53% in the year to Mar 2026.
Compared with Healthcare companies in India · latest annual results Mar 2026.
P/E ratio
42.0Investors pay ₹42.0 for every ₹1 of Jubilant Pharmova Limited's yearly profit, higher than 58% of Healthcare companies in India.
P/B ratio
2.08The share price is 2.08 times Jubilant Pharmova Limited's book value per share, lower than 87% of Healthcare companies in India.
Market cap
₹14,765 CrThe total market value of all of Jubilant Pharmova Limited's shares at today's price (share price × number of shares), larger than 71% of Healthcare companies in India. PosiCap size class: Meso Cap.
Net worth (book value)
₹7,093 CrWhat Jubilant Pharmova Limited would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (31 Mar 2026).
Book value per share
₹447.81Net worth divided by the number of shares. The share price of ₹932.20 is 2.1 times this, which is the P/B above.
Return on equity (ROE)
5.0%Jubilant Pharmova Limited earned 5.0% on its shareholders' money over the last year, lower than 82% of Healthcare companies in India.
Owes vs Owns
0.54×Jubilant Pharmova Limited owes ₹0.54 for every ₹1 it owns (moderate), higher than 87% of Healthcare companies in India.
Dividend yield
0.54%Jubilant Pharmova Limited pays 0.54% of its share price as dividends a year, higher than 65% of dividend-paying Healthcare companies in India.
Revenue growth
+14%Revenue rose 14% in the year to Mar 2026, and grew 10% a year on average over 3 years.
Profit growth
-53%Net profit fell 53% in the year to Mar 2026.
Profit margin
4.8%Jubilant Pharmova Limited keeps ₹5 of every ₹100 of revenue as net profit.
Cash quality
3.1×Cash from Jubilant Pharmova Limited's business was 3.1× its reported profit in the year to Mar 2026 — its profit turned into cash.
Interest cover
4.1×Jubilant Pharmova Limited's operating profit covered its interest costs 4.1 times in the year to Mar 2026.
Cash vs debt
Net debtJubilant Pharmova Limited had ₹2,332 Cr more debt than cash (net debt) at Mar 2026.
Questions
What is Jubilant Pharmova Limited's P/E ratio?
Investors pay ₹42.0 for every ₹1 of Jubilant Pharmova Limited's yearly profit, higher than 58% of Healthcare companies in India.
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Jubilant Pharmova Limited: ₹14,765 Cr ÷ ₹7,093 Cr (31 Mar 2026) = 2.1.
What is Jubilant Pharmova Limited's return on equity?
Jubilant Pharmova Limited earned 5.0% on its shareholders' money over the last year, lower than 82% of Healthcare companies in India.
How much does Jubilant Pharmova Limited owe compared with what it owns?
Jubilant Pharmova Limited owes ₹0.54 for every ₹1 it owns (moderate), higher than 87% of Healthcare companies in India.
Does Jubilant Pharmova Limited pay a dividend?
Yes. Jubilant Pharmova Limited pays 0.54% of its share price as dividends a year, higher than 65% of dividend-paying Healthcare companies in India.
Is Jubilant Pharmova Limited's revenue growing?
Revenue rose 14% in the year to Mar 2026, and grew 10% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.